MicroRNA‑370 suppresses the progression and proliferation of human astrocytoma and glioblastoma by negatively regulating β‑catenin and causing activation of FOXO3a

Lu,Ming; Wang,Yong; Zhou,Shizhen; Xu,Jun; Li,Jing; Tao,Rongjie; Zhu,Yufang

doi:10.3892/etm.2017.5494

MicroRNA‑370 suppresses the progression and proliferation of human astrocytoma and glioblastoma by negatively regulating β‑catenin and causing activation of FOXO3a

Authors:
- Ming Lu
- Yong Wang
- Shizhen Zhou
- Jun Xu
- Jing Li
- Rongjie Tao
- Yufang Zhu
View Affiliations

Affiliations: Department of Radiotherapy, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China, Department of Neurosurgery, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China
Published online on: November 13, 2017 https://doi.org/10.3892/etm.2017.5494
Pages: 1093-1098

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Certain microRNAs (miRs) regulate the progression and metastasis of various cancer types. In the present study, the role of miR‑370 in the progression and proliferation of human astrocytoma and glioblastoma cells was assessed and the underlying molecular mechanism was investigated. miR‑370 levels in clinical specimens of human glioma and peritumoral tissues were determined by reverse‑transcription quantitative PCR. Oligonucleotide mimics and inhibitors were transfected into the U‑251MG human astrocytoma cell line and the and U‑87MG glioblastoma cell line and the cell viability of was determined by an MTT assay. The expression of β‑catenin and forkhead box protein (FOX)O3a was determined by western blot analysis. The results revealed that the expression of miR‑370 in human glioma tissues was significantly decreased compared with that in peritumoral tissues. The miR‑370 levels in patients with grade III/IV gliomas were significantly decreased compared with those in grade I/II. Transfection with miR‑370 mimics inhibited the proliferation of U‑251MG and U‑87MG cells. Furthermore, the miR‑370 levels were negatively correlated with β‑catenin and positively correlated with nuclear FOXO3a. In conclusion, miR‑370 inhibited the proliferation of human glioma cells by regulating the levels of β‑catenin and the activation of FOXO3a, suggesting that miR‑370 was a tumor suppressor in the progression of human astrocytoma and glioblastoma cells.

View Figures

View References

1	Hirst TC, Vesterinen HM, Conlin S, Egan KJ, Antonic A, Lawson McLean A, Macleod MR, Grant R, Brennan PM, Sena ES and Whittle IR: A systematic review and meta-analysis of gene therapy in animal models of cerebral glioma: Why did promise not translate to human therapy? Evid Based Preclin Med. 1:e000062014. View Article : Google Scholar : PubMed/NCBI
2	Wang X, Chen JX, Zhou Q, Liu YH, Mao Q, You C, Chen N, Xiong L, Duan J and Liu L: Statistical report of central nervous system tumors histologically diagnosed in the sichuan province of China from 2008 to 2013: A west China glioma center report. Ann Surg Oncol. 23 Suppl 5:S946–S953. 2016. View Article : Google Scholar
3	Bauer R, Kaiser M and Stoll E: A computational model incorporating neural stem cell dynamics reproduces glioma incidence across the lifespan in the human population. PLoS One. 9:e1112192014. View Article : Google Scholar : PubMed/NCBI
4	Matyja E, Grajkowska W, Stepien K and Naganska E: Heterogeneity of histopathological presentation of pilocytic astrocytoma-diagnostic pitfalls. A review. Folia Neuropathol. 54:197–211. 2016. View Article : Google Scholar : PubMed/NCBI
5	Borghei-Razavi H, Shibao S and Schick U: Prechiasmatic transection of the optic nerve in optic nerve glioma: Technical description and surgical outcome. Neurosurg Rev. 40:135–141. 2017. View Article : Google Scholar : PubMed/NCBI
6	Luderer MJ, Muz B, de la Puente P, Chavalmane S, Kapoor V, Marcelo R, Biswas P, Thotala D, Rogers B and Azab AK: A hypoxia-targeted boron neutron capture therapy agent for the treatment of glioma. Pharm Res. 33:2530–2539. 2016. View Article : Google Scholar : PubMed/NCBI
7	Bouffet E and Ramaswamy V: Old chemotherapy makes a comeback: Dual alkylator therapy for pediatric high-grade glioma. Neuro Oncol. 18:1333–1334. 2016. View Article : Google Scholar : PubMed/NCBI
8	Cordier D, Krolicki L, Morgenstern A and Merlo A: Targeted radiolabeled compounds in glioma therapy. Semin Nucl Med. 46:243–249. 2016. View Article : Google Scholar : PubMed/NCBI
9	Barajas RF Jr, Butowski NA, Phillips JJ, Aghi MK, Berger MS, Chang SM and Cha S: The development of reduced diffusion following bevacizumab therapy identifies regions of recurrent disease in patients with high-grade glioma. Acad Radiol. 23:1073–1082. 2016. View Article : Google Scholar : PubMed/NCBI
10	Cai Y, Yu X, Hu S and Yu J: A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics. 7:147–154. 2009. View Article : Google Scholar : PubMed/NCBI
11	Xu X, Yang X, Xing C, Zhang S and Cao J: miRNA: The nemesis of gastric cancer (Review). Oncol Lett. 6:631–641. 2013.PubMed/NCBI
12	Ma H, Wu Y, Yang H, Liu J, Dan H, Zeng X, Zhou Y, Jiang L and Chen Q: MicroRNAs in oral lichen planus and potential miRNA-mRNA pathogenesis with essential cytokines: A review. Oral Surg Oral Med Oral Pathol Oral Radiol. 122:164–173. 2016. View Article : Google Scholar : PubMed/NCBI
13	Mehta R, Otgonsuren M, Younoszai Z, Allawi H, Raybuck B and Younossi Z: Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease. BMJ Open Gastroenterol. 3:e0000962016. View Article : Google Scholar : PubMed/NCBI
14	Srinivasan H and Das S: Mitochondrial miRNA (MitomiR): A new player in cardiovascular health. Can J Physiol Pharmacol. 93:855–861. 2015. View Article : Google Scholar : PubMed/NCBI
15	Daimiel-Ruiz L, Klett-Mingo M, Konstantinidou V, Micó V, Aranda JF, García B, Martínez-Botas J, Dávalos A, Fernández-Hernando C and Ordovás JM: Dietary lipids modulate the expression of miR-107, a miRNA that regulates the circadian system. Mol Nutr Food Res. 59:1865–1878. 2015. View Article : Google Scholar : PubMed/NCBI
16	Zhou X, Jeker LT, Fife BT, Zhu S, Anderson MS, McManus MT and Bluestone JA: Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med. 205:1983–1991. 2008. View Article : Google Scholar : PubMed/NCBI
17	Shaked A, Chang BL, Barnes MR, Sayre P, Li YR, Asare S, DesMarais M, Holmes MV, Guettouche T and Keating BJ: An ectopically expressed serum miRNA signature is prognostic, diagnostic, and biologically related to liver allograft rejection. Hepatology. 65:269–280. 2017. View Article : Google Scholar : PubMed/NCBI
18	Cramer DW and Elias KM: A prognostically relevant miRNA signature for epithelial ovarian cancer. Lancet Oncol. 17:1032–1033. 2016. View Article : Google Scholar : PubMed/NCBI
19	Lin YC, Lin JF, Tsai TF, Chou KY, Chen HE and Hwang TI: Tumor suppressor miRNA-204-5p promotes apoptosis by targeting BCL2 in prostate cancer cells. Asian J Surg. 40:396–406. 2017. View Article : Google Scholar : PubMed/NCBI
20	Zhang X, Zeng J, Zhou M, Li B, Zhang Y, Huang T, Wang L, Jia J and Chen C: The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia. Mol Cancer. 11:562012. View Article : Google Scholar : PubMed/NCBI
21	Mollainezhad H, Eskandari N, Pourazar A, Salehi M and Andalib A: Expression of microRNA-370 in human breast cancer compare with normal samples. Adv Biomed Res. 5:1292016. View Article : Google Scholar : PubMed/NCBI
22	Peng Z, Wu T, Li Y, Xu Z, Zhang S, Liu B, Chen Q and Tian D: MicroRNA-370-3p inhibits human glioma cell proliferation and induces cell cycle arrest by directly targeting β-catenin. Brain Res. 1644:53–61. 2016. View Article : Google Scholar : PubMed/NCBI
23	Allen M, Bjerke M, Edlund H, Nelander S and Westermark B: Origin of the U87MG glioma cell line: Good news and bad news. Sci Transl Med. 8:354re32016. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Yang M, Pi H, Li M, Xu S, Zhang L, Xie J, Tian L, Tu M, He M, Lu Y, et al: From the Cover: Autophagy induction contributes to cadmium toxicity in Mesenchymal stem cells via AMPK/FOXO3a/BECN1 signaling. Toxicol Sci. 154:101–114. 2016. View Article : Google Scholar : PubMed/NCBI
26	Sun G, Hou YB, Jia HY, Bi XH, Yu L and Chen DJ: MiR-370 promotes cell death of liver cancer cells by Akt/FoxO3a signalling pathway. Eur Rev Med Pharmacol Sci. 20:2011–2019. 2016.PubMed/NCBI
27	Denysenko T, Annovazzi L, Cassoni P, Melcarne A, Mellai M and Schiffer D: WNT/β-catenin signaling pathway and downstream modulators in low- and high-grade glioma. Cancer Genomics Proteomics. 13:31–45. 2016.PubMed/NCBI
28	Guan H, Song L, Cai J, Huang Y, Wu J, Yuan J, Li J and Li M: Sphingosine kinase 1 regulates the Akt/FOXO3a/Bim pathway and contributes to apoptosis resistance in glioma cells. PLoS One. 6:e199462011. View Article : Google Scholar : PubMed/NCBI
29	Amberger VR, Hensel T, Ogata N and Schwab ME: Spreading and migration of human glioma and rat C6 cells on central nervous system myelin in vitro is correlated with tumor malignancy and involves a metalloproteolytic activity. Cancer Res. 58:149–158. 1998.PubMed/NCBI